Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Botanical decision model to identify evidence thresholds suggested by OAM's Jonas.

This article was originally published in The Tan Sheet

Executive Summary

BOTANICAL CLINICAL EVALUATION MODEL TO ALLOW "INTERMEDIATE DECISIONS" on the usefulness of a substance was suggested by NIH Office of Complementary and Alternative Medicine Director Wayne Jonas, MD, at a Drug Information Association meeting in Washington, D.C. Jan. 28. Jonas discussed an approach for botanicals that he said "might allow us to break out of the rigid boundaries" of current clinical efficacy testing requirements and allow for a less expensive, less complicated testing program.
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS086621

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel